Prostate cancer screening for men over 70 is complex, with current recommendations against routine PSA testing due to slow ...

Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive ...

A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...

Targeting prostate-specific membrane antigen, Lu-PSMA-617 has demonstrated clinical benefits in patients with PSMA-positive ...

New findings from the EMBARK trial reveal enzalutamide significantly reduces mortality risk in high-risk prostate cancer ...

Enzalutamide plus leuprolide reduces the risk of death by more than 40% in biochemically recurrent prostate cancer compared to leuprolide alone.

Anti-tumor activity was observed in heavily pretreated mCRPC patients across all dose cohorts; in 22 patients who completed at least 2 cycles of therapy, 59% achieved PSA50 response and 32% achieved P ...

A globally-renowned prostate cancer surgeon shares the latest advancements in the field and stresses the importance of early ...

A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer, ...

The trial will test 10,000 scans at up to 15 hospitals across the country and will be rolled out nationally if successful.

Scott Tagawa, MD, highlights the PSMAddition trial's promising results, showcasing Lutetium-177 PSMA-617's significant ...

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in ...